Shire Offers to Buy Baxalta for $30 Billion

Shire said it has offered to acquire Baxalta in an all-share deal valued at roughly $30.6 billion, in a combination what would create a leader in treatments for rare diseases.

from WSJ.com: US Business http://ift.tt/1IgXOKl
via IFTTT